Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ICMT | O60725 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.30 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.30 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12847596 | 1.00 | LMNA (0.41) | LMNAKDM4EMAPTALOX15SMN1; SMN2 | |
| SCHEMBL12847696 | 1.00 | LMNA (0.41) | LMNAKDM4EMAPTALOX15SMN1; SMN2 | |
| SCHEMBL12847697 | 0.92 | LMNA (0.39) | LMNAKDM4EMAPTALOX15SMN1; SMN2 | |
| SCHEMBL12791476 | 0.91 | LMNA (0.48) | LMNAKDM4EALOX15ICMTALB | |
| SCHEMBL12791503 | 0.91 | LMNA (0.48) | LMNAKDM4EALOX15ICMTALB | |
| SCHEMBL12791820 | 0.88 | LMNA (0.36) | LMNA | |
| SCHEMBL10820679 | 0.85 | LMNA (0.34) | LMNA | |
| SCHEMBL12847597 | 0.85 | LMNA (0.34) | LMNA | |
| SCHEMBL12847504 | 0.85 | LMNA (0.40) | LMNAKDM4EICMTALBPOLB | |
| SCHEMBL24602045 | 0.84 | LMNA (0.43) | LMNAICMTALBPOLBMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110052673-A1 | THERAPEUTIC COMPOSITIONS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2011-03-03 | — | — | US | disclosed |
| US-20110009641-A1 | Amine-containing lipids and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052673-A1 | THERAPEUTIC COMPOSITIONS | PHOSPHO1, SGMS1, APOB | LMNA 536/4885KDM4E 2558/4885MAPT 513/4885 |
| US-20110009641-A1 | Amine-containing lipids and uses thereof | PHOSPHO1, CHMP4B, SGMS1 | LMNA 402/4885KDM4E 2172/4885MAPT 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.